(mentions CMT) Vista Partners and Avicena

[Guest guest]

Vista Partners Raises Twelve Month Target Price on Avicena Group to

$12.00 per Share and Updates Coverage

http://biz./prnews/061214/sfth052.html?.v=80

SAN FRANCISCO, Dec. 14 /PRNewswire/ -- Vista Partners has raised its

twelve month target price on Avicena Group (OTC Bulletin Board:

AVGO - News). Avicena recently announced that its lead compound for

Parkinson's Disease, with an estimated $8 billion global market, is

entering phase III clinical trials in partnership with the National

Institute of Neurological Disorders and Stroke (NINDS). Avicena also

announced that its lead compound for Huntington's Disease will enter

phase III clinical trials in 2007 upon completion of a chronic

toxicology study.

The company will now have 3 drugs in Phase III clinical trials in

2007 (ALS, Parkinson's and Huntington's) and 3 additional drugs

advancing through phase I trials (Creatine Transporter Defect,

Duchenne Muscular Dystrophy, Charcot-Marie Tooth Syndrome), giving

the company one of the most robust central nervous system (CNS)

pipelines amongst biotechnology companies.

The company remains relatively undiscovered and we believe it should

trade in line with premium valued CNS companies.

Vista Partners provides independent, equity research to

institutional and individual investors, with a focus on publicly

traded small capitalization companies. Ross Silver of Vista Partners

issued the report. For more information and to download the report;

please visit the Vista Partners website at www.vistap.com .

The Avicena Group, Inc. is a late stage, revenue generating

biotechnology company focused on developing products based on its

proprietary understanding of the regulation of cellular energy

processes. The company's core technologies, supported by a robust IP

portfolio, have broad applications in both pharmaceuticals and

dermaceuticals. Avicena's pharmaceutical program centers on rare

neurological disorders (orphan diseases). The company is currently

analyzing data from its Phase IIb/ III trial in ALS (Amyotrophic

Lateral Sclerosis, or Lou Gehrig's Disease). Near term, Avicena

intends to initiate both a Phase III trial in Huntington's Disease

and a Phase III trial in Parkinson's Disease. Avicena presently

derives revenue from the sale of proprietary ingredients to skin

care manufacturers. Furthermore, the company is developing a

proprietary line of therapeutic skin care products. Avicena's

science is well established and its products are safe and well

tolerated. Unlike traditional biotechnology companies, Avicena's

clinical programs are largely funded by government and non-profit

organizations.